Anagrelide in essential thrombocythemia: Efficacy and long-term consequences in young patient population.

According to the current treatment recommendations, anagrelide, an oral antiplatelet agent, is recommended as a second-line therapy for patients with high-risk essential thrombocythemia experiencing intolerance or refractoriness to first-line approach, such as hydroxyurea or pegylated interferon alpha-2a. If there is a need for introduction of cytoreductive treatment in young patients with a perspective of lifelong exposure, both the efficacy and long-term outcomes should be known. We present the analysis of 48 young patients, diagnosed with essential thrombocythemia below the age of 60, who were exposed to anagrelide treatment for over 10 years. Our observations show that the highest proportion of complete remissions without adverse events and disease progression is seen in the JAK2 -mutated patients. By evaluating the changes in hemoglobin concentration and serum erythropoietin throughout the study, we were able to reveal the development of progressive anemia, resulting from diminished susceptibility to erythropoietin and unrelated to bone marrow fibrosis, in patients harboring CALR mutation. Additionally, occurrence of new bone marrow fibrosis was confirmed in seven JAK2- unmutated patients at the end of the study. In summary, in young patient population, we recommend limiting the use of anagrelide to JAK2- mutated subgroup, reducing exposure time and underline the importance of periodic monitoring for the presence of bone marrow fibrosis. • Long-time anagrelide exposure results in progressive anemia in ET patients. • Anagrelide pro-anemic effect is driven by erythropoietin resistance. • CALR- mutated patients are particularly susceptible to anagrelide-induced anemia. [ABSTRACT FROM AUTHOR]